Line 1: |
Line 1: |
| + | '''Table 1 - Clinically significant cytogenomic alterations in plasma cell myeloma (Literature Review)'''. Summary table reviewing 65 papers applying FISH, CMA, NGS, and gene expression profiling for PCN diagnosis and prognosis. See Table 2 for references and Level 3 evidence. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. |
| + | {| class="wikitable" |
| + | |'''Evidence Level''' |
| + | |'''Chromosomal Abnormality''' |
| + | |'''Significance''' |
| + | |'''Genes''' |
| + | |- |
| + | | rowspan="11" |'''Level 1''' |
| + | |
| + | well established evidence in NCCN guideline, |
| + | |
| + | WHO criteria, FDA-approved, COG |
| + | |
| + | recommendation, or based on large body of publications. |
| + | |Hyperdiploidy (+3, +5, +7, +9, +11, +15, +21) |
| + | |Good prognosis |
| + | | |
| + | |- |
| + | |t(4;14) |
| + | |Poor prognosis, predicts bortezomib response |
| + | |''[[IGH]]'' |
| + | |- |
| + | |t(6;14) |
| + | |Good prognosis |
| + | |''[[IGH]]'' |
| + | |- |
| + | |t(14;16) |
| + | |Poor prognosis |
| + | |''[[IGH]]'' |
| + | |- |
| + | |t(11;14) |
| + | |Good prognosis |
| + | |''[[IGH]]'' |
| + | |- |
| + | |t(14;20) |
| + | |Poor prognosis |
| + | | |
| + | |- |
| + | |del(1p) |
| + | |Poor prognosis |
| + | | |
| + | |- |
| + | |1q+ |
| + | |Poor prognosis |
| + | | |
| + | |- |
| + | |del(13q) |
| + | |Poor prognosis |
| + | | |
| + | |- |
| + | |16q |
| + | |Poor prognosis |
| + | | |
| + | |- |
| + | |del(17p) |
| + | |Poor prognosis (Level 1), predicts response (Level 2) |
| + | | |
| + | |- |
| + | | rowspan="27" |'''Level 2''' |
| + | |
| + | emerging evidence by one large study or multiple case reports |
| + | |1p CN-LOH |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |<nowiki>+2</nowiki> |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(4q) |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(5p), 5q+, del(5q) |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |6p+ |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(6q) |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |7q+ |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(8p) |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |8q24.2+ |
| + | |Recurrent |
| + | |''[[MYC]]'' |
| + | |- |
| + | |9p+ |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(10q23.31) |
| + | |Recurrent |
| + | |''[[PTEN]]'' |
| + | |- |
| + | |11q+ |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(12p) or 12p CN-LOH |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(13q32.2) |
| + | |Recurrent |
| + | |''[[TGDS]]'' |
| + | |- |
| + | |del(14q) |
| + | |Good prognosis |
| + | | |
| + | |- |
| + | | 14q CN-LOH |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |16 CN-LOH |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |17 CN-LOH |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |17q25+ |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |<nowiki>+18</nowiki> |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |<nowiki>+19, 19q+</nowiki> |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(20p) |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |<nowiki>+20, 20q+</nowiki> |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |del(22) |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |22q21+ |
| + | |Associated with relapse |
| + | |''[[PRAME]]'' |
| + | |- |
| + | |del(X), X+, X CN-LOH |
| + | |Recurrent |
| + | | |
| + | |- |
| + | |Xq+ in males |
| + | |Poor prognosis |
| + | | |
| + | |} |
| + | |
| + | |
| + | '''Table 2 - Recurrent Abnormalities of copy number aberration (CNAs) and copy-neutral loss-of-heterozygosity (cnLOH) in plasma cell myeloma (Literature Review)'''. Table derived from Pugh et al., 2018 [PMID 30393007] with permission from Cancer Genetics. |
| {| class="wikitable" | | {| class="wikitable" |
| |'''Chromosome''' | | |'''Chromosome''' |
Line 6: |
Line 178: |
| |'''Significance (Recurrent, Diagnostic, Prognostic, Targeted treatment)''' | | |'''Significance (Recurrent, Diagnostic, Prognostic, Targeted treatment)''' |
| |'''Strength of Evidence (Level 1, 2, 3, see legend below table for criteria)''' | | |'''Strength of Evidence (Level 1, 2, 3, see legend below table for criteria)''' |
− | |'''References PMID (year)''' | + | |'''References''' |
| |- | | |- |
| | rowspan="9" |1 | | | rowspan="9" |1 |
| |1p32 | | |1p32 |
| |Loss | | |Loss |
− | |''FAF1, CDKN2C'' | + | |''[[FAF1]], [[CDKN2C]]'' |
| |Poor prognostic marker | | |Poor prognostic marker |
| |1, 2 | | |1, 2 |
− | |<ref name=":0">{{Cite journal|last=B|first=Hebraud|last2=F|first2=Magrangeas|last3=A|first3=Cleynen|last4=V|first4=Lauwers-Cances|last5=Ml|first5=Chretien|last6=C|first6=Hulin|last7=X|first7=Leleu|last8=E|first8=Yon|last9=G|first9=Marit|date=2015|title=Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience|url=https://pubmed.ncbi.nlm.nih.gov/25636340/|language=en|doi=10.1182/blood-2014-07-587964|pmc=PMC4375107|pmid=25636340}}</ref> 24987674 (2014)<ref name=":1">{{Cite journal|last=J|first=Smetana|last2=J|first2=Frohlich|last3=R|first3=Zaoralova|last4=V|first4=Vallova|last5=H|first5=Greslikova|last6=R|first6=Kupska|last7=P|first7=Nemec|last8=A|first8=Mikulasova|last9=M|first9=Almasi|date=2014|title=Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience|url=https://pubmed.ncbi.nlm.nih.gov/24987674/|language=en|doi=10.1155/2014/209670|pmc=PMC4060785|pmid=24987674}}</ref>, 25145975 (2015)<ref name=":2">{{Cite journal|last=M|first=Kim|last2=Sh|first2=Lee|last3=J|first3=Kim|last4=Se|first4=Lee|last5=Yj|first5=Kim|last6=Ck|first6=Min|date=2015|title=Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/25145975/|language=en|pmid=25145975}}</ref> | + | |<ref name=":0">{{Cite journal|last=B|first=Hebraud|last2=F|first2=Magrangeas|last3=A|first3=Cleynen|last4=V|first4=Lauwers-Cances|last5=Ml|first5=Chretien|last6=C|first6=Hulin|last7=X|first7=Leleu|last8=E|first8=Yon|last9=G|first9=Marit|date=2015|title=Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience|url=https://pubmed.ncbi.nlm.nih.gov/25636340/|language=en|doi=10.1182/blood-2014-07-587964|pmc=PMC4375107|pmid=25636340}}</ref> <ref name=":1">{{Cite journal|last=J|first=Smetana|last2=J|first2=Frohlich|last3=R|first3=Zaoralova|last4=V|first4=Vallova|last5=H|first5=Greslikova|last6=R|first6=Kupska|last7=P|first7=Nemec|last8=A|first8=Mikulasova|last9=M|first9=Almasi|date=2014|title=Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience|url=https://pubmed.ncbi.nlm.nih.gov/24987674/|language=en|doi=10.1155/2014/209670|pmc=PMC4060785|pmid=24987674}}</ref> <ref name=":2">{{Cite journal|last=M|first=Kim|last2=Sh|first2=Lee|last3=J|first3=Kim|last4=Se|first4=Lee|last5=Yj|first5=Kim|last6=Ck|first6=Min|date=2015|title=Copy number variations could predict the outcome of bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/25145975/|language=en|pmid=25145975}}</ref> |
| |- | | |- |
| |1p22.2-p22.1 | | |1p22.2-p22.1 |
| |Loss | | |Loss |
− | |''BARHL2, TGFBR3, and others; HSP90B3P, TGFER3, BRDT, EPHAX4, BTBD8'' | + | |''[[BARHL2]], [[TGFBR3]], and others; [[HSP90B3P]], [[TGFER3]], [[BRDT]], [[EPHAX4]], [[BTBD8]]'' |
| |Prognostic | | |Prognostic |
| |1, 3 | | |1, 3 |
− | |24987674 (2014)<ref name=":1" /> 25145975 (2015)<ref name=":2" /> 26912802 (2016)<ref name=":3">{{Cite journal|last=E|first=Kjeldsen|date=2016|title=Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling|url=https://pubmed.ncbi.nlm.nih.gov/26912802/|language=en|pmid=26912802}}</ref> | + | |<ref name=":1" /> <ref name=":2" /> <ref name=":3">{{Cite journal|last=E|first=Kjeldsen|date=2016|title=Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling|url=https://pubmed.ncbi.nlm.nih.gov/26912802/|language=en|pmid=26912802}}</ref> |
| |- | | |- |
| |1p21.3 | | |1p21.3 |
| |Loss | | |Loss |
− | |''SNX7'' | + | |''[[SNX7]]'' |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |24429703-(2014)<ref name=":4">{{Cite journal|last=N|first=Bolli|last2=H|first2=Avet-Loiseau|last3=Dc|first3=Wedge|last4=P|first4=Van Loo|last5=Lb|first5=Alexandrov|last6=I|first6=Martincorena|last7=Kj|first7=Dawson|last8=F|first8=Iorio|last9=S|first9=Nik-Zainal|date=2014|title=Heterogeneity of genomic evolution and mutational profiles in multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/24429703/|language=en|doi=10.1038/ncomms3997|pmc=PMC3905727|pmid=24429703}}</ref> | + | |<ref name=":4">{{Cite journal|last=N|first=Bolli|last2=H|first2=Avet-Loiseau|last3=Dc|first3=Wedge|last4=P|first4=Van Loo|last5=Lb|first5=Alexandrov|last6=I|first6=Martincorena|last7=Kj|first7=Dawson|last8=F|first8=Iorio|last9=S|first9=Nik-Zainal|date=2014|title=Heterogeneity of genomic evolution and mutational profiles in multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/24429703/|language=en|doi=10.1038/ncomms3997|pmc=PMC3905727|pmid=24429703}}</ref> |
| |- | | |- |
| |1p13.2 | | |1p13.2 |
| |Loss | | |Loss |
− | |MAG13(kinase), BCL2 like and others | + | |''[[MAGI3]]'', BCL2 like and others |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5">{{Cite journal|last=T|first=Boneva|last2=D|first2=Brazma|last3=K|first3=Gancheva|last4=J|first4=Howard-Reeves|last5=J|first5=Raynov|last6=C|first6=Grace|last7=Ep|first7=Nacheva|date=2014|title=Can genome array screening replace FISH as a front-line test in multiple myeloma?|url=https://pubmed.ncbi.nlm.nih.gov/24757046/|language=en|pmid=24757046}}</ref> | + | |<ref name=":5">{{Cite journal|last=T|first=Boneva|last2=D|first2=Brazma|last3=K|first3=Gancheva|last4=J|first4=Howard-Reeves|last5=J|first5=Raynov|last6=C|first6=Grace|last7=Ep|first7=Nacheva|date=2014|title=Can genome array screening replace FISH as a front-line test in multiple myeloma?|url=https://pubmed.ncbi.nlm.nih.gov/24757046/|language=en|pmid=24757046}}</ref> |
| |- | | |- |
| |1p12 | | |1p12 |
| |Loss | | |Loss |
− | |''MAN1A2, FAM46C, GDAP2'' | + | |''[[MAN1A2]], [[FAM46C]], [[GDAP2]]'' |
| |Recurrent | | |Recurrent |
− | |2 | + | | 2 |
− | |<ref name=":0" /> 24987674 (2014)<ref name=":1" /> | + | |<ref name=":0" /> <ref name=":1" /> |
| |- | | |- |
| |1p | | |1p |
Line 49: |
Line 221: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" /> | + | |<ref name=":2" /> |
| |- | | |- |
| |1p | | |1p |
Line 56: |
Line 228: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |23010713 (2012)<ref name=":6">{{Cite journal|last=Bk|first=Zehentner|last2=L|first2=Hartmann|last3=Kr|first3=Johnson|last4=Cf|first4=Stephenson|last5=Db|first5=Chapman|last6=Me|first6=de Baca|last7=Da|first7=Wells|last8=Mr|first8=Loken|last9=B|first9=Tirtorahardjo|date=2012|title=Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations|url=https://pubmed.ncbi.nlm.nih.gov/23010713/|language=en|pmid=23010713}}</ref>, 22833442 (2012)<ref name=":7">{{Cite journal|last=M|first=Stevens-Kroef|last2=Do|first2=Weghuis|last3=S|first3=Croockewit|last4=L|first4=Derksen|last5=J|first5=Hooijer|last6=N|first6=Elidrissi-Zaynoun|last7=A|first7=Siepman|last8=A|first8=Simons|last9=Ag|first9=Kessel|date=2012|title=High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/22833442/|language=en|pmid=22833442}}</ref>, 24987674 (2014)<ref name=":1" />, 27588520 (2016)<ref name=":8">{{Cite journal|last=N|first=Bolli|last2=Y|first2=Li|last3=V|first3=Sathiaseelan|last4=K|first4=Raine|last5=D|first5=Jones|last6=P|first6=Ganly|last7=F|first7=Cocito|last8=G|first8=Bignell|last9=Ma|first9=Chapman|date=2016|title=A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/27588520/|language=en|doi=10.1038/bcj.2016.72|pmc=PMC5056967|pmid=27588520}}</ref>, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6">{{Cite journal|last=Bk|first=Zehentner|last2=L|first2=Hartmann|last3=Kr|first3=Johnson|last4=Cf|first4=Stephenson|last5=Db|first5=Chapman|last6=Me|first6=de Baca|last7=Da|first7=Wells|last8=Mr|first8=Loken|last9=B|first9=Tirtorahardjo|date=2012|title=Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrations|url=https://pubmed.ncbi.nlm.nih.gov/23010713/|language=en|pmid=23010713}}</ref> <ref name=":7">{{Cite journal|last=M|first=Stevens-Kroef|last2=Do|first2=Weghuis|last3=S|first3=Croockewit|last4=L|first4=Derksen|last5=J|first5=Hooijer|last6=N|first6=Elidrissi-Zaynoun|last7=A|first7=Siepman|last8=A|first8=Simons|last9=Ag|first9=Kessel|date=2012|title=High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/22833442/|language=en|pmid=22833442}}</ref> <ref name=":8">{{Cite journal|last=N|first=Bolli|last2=Y|first2=Li|last3=V|first3=Sathiaseelan|last4=K|first4=Raine|last5=D|first5=Jones|last6=P|first6=Ganly|last7=F|first7=Cocito|last8=G|first8=Bignell|last9=Ma|first9=Chapman|date=2016|title=A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/27588520/|language=en|doi=10.1038/bcj.2016.72|pmc=PMC5056967|pmid=27588520}}</ref> |
| |- | | |- |
| |1q21.2-q23 | | |1q21.2-q23 |
| |Gain | | |Gain |
− | |''CKS1B'' and ''ANP32E'' | + | |''[[CKS1B]]'' and ''[[ANP32E]]'' |
| |Recurrent | | |Recurrent |
− | |1 | + | | 1 |
− | |23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 27588520 (2016)<ref name=":8" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> <ref name=":8" /> |
| |- | | |- |
| |1q | | |1q |
− | |Gain | + | | Gain |
| | | | | |
| |Poor prognostic marker | | |Poor prognostic marker |
| |1 | | |1 |
− | |23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| | rowspan="2" |2 | | | rowspan="2" |2 |
Line 78: |
Line 250: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" /> | + | |<ref name=":7" /> |
| |- | | |- |
| |2q | | |2q |
Line 85: |
Line 257: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |23010713 (2012)<ref name=":6" /> | + | |<ref name=":6" /> |
| |- | | |- |
| | rowspan="2" |3 | | | rowspan="2" |3 |
Line 93: |
Line 265: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |3q21-23 | | |3q21-23 |
Line 100: |
Line 272: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" /> | + | |<ref name=":2" /> |
| |- | | |- |
| | rowspan="3" |4 | | | rowspan="3" |4 |
| |4p16.3 | | |4p16.3 |
| |Loss | | |Loss |
− | |''FGFR3'' and ''WHSC1'' | + | |''[[FGFR3]]'' and ''[[WHSC1]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |4p15.2 | | |4p15.2 |
| |Loss | | |Loss |
− | |''LGI2, SEPSECS, PI4K2B'' and others | + | |''[[LGI2]], [[SEPSECS]], [[PI4K2B]]'' and others |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |4q35.1 | | |4q35.1 |
| |Loss | | |Loss |
− | |''DCTD, ING2,'' and others | + | |''[[DCTD]], [[ING2]]'' and others |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| | rowspan="6" |5 | | | rowspan="6" |5 |
| |5 | | |5 |
− | |Gain | + | | Gain |
| | | | | |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 27588520 (2016)<ref name=":8" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> <ref name=":8" /> |
| |- | | |- |
| |5p | | |5p |
Line 137: |
Line 309: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |5p | | |5p |
Line 144: |
Line 316: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" /> | + | |<ref name=":7" /> |
| |- | | |- |
| |5p14.3 | | |5p14.3 |
| |Gain | | |Gain |
− | |''CDH12,10'' | + | |''[[CDH10]], [[CDH12]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5" /> | + | |<ref name=":5" /> |
| |- | | |- |
| |5q | | |5q |
Line 157: |
Line 329: |
| | | | | |
| |Recurrent | | |Recurrent |
− | |2 | + | | 2 |
− | |25145975 (2015)<ref name=":2" /> 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":2" /> |
| |- | | |- |
| |5q13.2 | | |5q13.2 |
| |Loss | | |Loss |
− | |''OCLN, NAIP'', and others | + | |''[[OCLN]], [[NAIP]]'' and others |
− | |Recurrent | + | | Recurrent |
| |2 | | |2 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
− | | rowspan="7" |6 | + | | rowspan="6" |6 |
| |6p | | |6p |
| |Gain | | |Gain |
Line 173: |
Line 345: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":7" /> |
| |- | | |- |
| |6pter-p22.3 | | |6pter-p22.3 |
Line 180: |
Line 352: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |6q | | |6q |
Line 187: |
Line 359: |
| |Poor prognostic marker | | |Poor prognostic marker |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" /> 25145975 (2015)<ref name=":2" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":2" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |6q11.1-q13 | | |6q11.1-q13 |
| |Gain | | |Gain |
− | |''MTRNR2L9'' | + | |''[[MTRNR2L9]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |6q16.3 | | |6q16.3 |
| |Loss | | |Loss |
− | |''COQR, GRIK2'' | + | |''[[COQR]], [[GRIK2]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |6q25.3 | | |6q25.3 |
| |Loss | | |Loss |
− | |''IGFR3'' | + | |''[[IGFR3]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5" /> | + | |<ref name=":5" /> |
− | |-
| |
− | |6q16.3
| |
− | |Loss
| |
− | |''COQR, GRIK2''
| |
− | |Recurrent
| |
− | |3
| |
− | |24987674 (2014)<ref name=":1" />
| |
| |- | | |- |
| | rowspan="4" |7 | | | rowspan="4" |7 |
Line 223: |
Line 388: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |7p | | |7p |
Line 230: |
Line 395: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |7p15.2 | | |7p15.2 |
| |Gain | | |Gain |
− | |''CBX3, etc'' | + | |''[[CBX3]]'', etc |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |7q | | |7q |
Line 244: |
Line 409: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" />, 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":2" /> |
| |- | | |- |
| | rowspan="6" |8 | | | rowspan="6" |8 |
Line 252: |
Line 417: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" /> 25145975 (2015)<ref name=":2" /> 24757046 (2014)<ref name=":5" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":2" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
− | |8p23.1 | + | | 8p23.1 |
| |Loss | | |Loss |
− | |''DEFB4'' and others | + | |''[[DEFB4]]'' and others |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |8p21.3/p21.2 | | |8p21.3/p21.2 |
| |Loss | | |Loss |
− | |''TNFRSF10B, DOCK5'' and others | + | |''[[TNFRSF10B]], [[DOCK5]]'' and others |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5" /> | + | |<ref name=":5" /> |
| |- | | |- |
| |8q | | |8q |
Line 272: |
Line 437: |
| | | | | |
| |Recurrent | | |Recurrent |
− | |3 | + | | 3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |8q24.2 | | |8q24.2 |
| |Gain/amplification and Loss | | |Gain/amplification and Loss |
− | |''MYC'' | + | |''[[MYC]]'' |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |24757046 (2014)<ref name=":5" />, 27588520 (2016)<ref name=":8" />, 26338801 (2016)<ref>{{Cite journal|last=K|first=Rack|last2=S|first2=Vidrequin|last3=Jl|first3=Dargent|date=2016|title=Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases|url=https://pubmed.ncbi.nlm.nih.gov/26338801/|language=en|pmid=26338801}}</ref>, 24987674 (2014)<ref name=":1" />, 27811368-(2016)<ref name=":9">{{Cite journal|last=P|first=Krzeminski|last2=La|first2=Corchete|last3=Jl|first3=García|last4=L|first4=López-Corral|last5=E|first5=Fermiñán|last6=Em|first6=García|last7=Aa|first7=Martín|last8=Jm|first8=Hernández-Rivas|last9=R|first9=García-Sanz|date=2016|title=Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse|url=https://pubmed.ncbi.nlm.nih.gov/27811368/|language=en|doi=10.18632/oncotarget.13025|pmc=PMC5348347|pmid=27811368}}</ref> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":8" /> <ref>{{Cite journal|last=K|first=Rack|last2=S|first2=Vidrequin|last3=Jl|first3=Dargent|date=2016|title=Genomic profiling of myeloma: the best approach, a comparison of cytogenetics, FISH and array-CGH of 112 myeloma cases|url=https://pubmed.ncbi.nlm.nih.gov/26338801/|language=en|pmid=26338801}}</ref> <ref name=":9">{{Cite journal|last=P|first=Krzeminski|last2=La|first2=Corchete|last3=Jl|first3=García|last4=L|first4=López-Corral|last5=E|first5=Fermiñán|last6=Em|first6=García|last7=Aa|first7=Martín|last8=Jm|first8=Hernández-Rivas|last9=R|first9=García-Sanz|date=2016|title=Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse|url=https://pubmed.ncbi.nlm.nih.gov/27811368/|language=en|doi=10.18632/oncotarget.13025|pmc=PMC5348347|pmid=27811368}}</ref> |
| |- | | |- |
| |8q24.3 | | |8q24.3 |
− | |Gain | + | | Gain |
− | |''MAPK15, TOP1MT, CYP11B11 (P450), ZNF41, 616, 707'' and ''ZNF517'' | + | |''[[MAPK15]], [[TOP1MT]], [[CYP11B11]] (P450), [[ZNF41]], [[ZNF517]], [[ZNF616]]'' and ''[[ZNF707]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5" />, 27811368-(2016)<ref name=":9" /> | + | |<ref name=":5" /> <ref name=":9" /> |
| |- | | |- |
| | rowspan="4" |9 | | | rowspan="4" |9 |
Line 295: |
Line 460: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
− | |9p | + | | 9p |
| |Gain | | |Gain |
| | | | | |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" /> 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":2" /> |
| |- | | |- |
| |9q | | |9q |
Line 309: |
Line 474: |
| |Recurrent | | |Recurrent |
| | | | | |
− | |25145975 (2015)<ref name=":2" /> 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":2" /> |
| |- | | |- |
| |9q34.3 | | |9q34.3 |
| |Gain | | |Gain |
− | |''ZNF79, CDK9, SET'' | + | |''[[ZNF79]], [[CDK9]], SET'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5" /> | + | |<ref name=":5" /> |
| |- | | |- |
| | rowspan="3" |10 | | | rowspan="3" |10 |
Line 324: |
Line 489: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |10q | | |10q |
Line 331: |
Line 496: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |10q23.31 | | |10q23.31 |
| |Loss | | |Loss |
− | |''PTEN'' | + | |''[[PTEN]]'' |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |16112193 (2006)<ref>{{Cite journal|last=H|first=Chang|last2=Xy|first2=Qi|last3=J|first3=Claudio|last4=L|first4=Zhuang|last5=B|first5=Patterson|last6=Ak|first6=Stewart|date=2006|title=Analysis of PTEN deletions and mutations in multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/16112193/|language=en|pmid=16112193}}</ref> | + | |<ref>{{Cite journal|last=H|first=Chang|last2=Xy|first2=Qi|last3=J|first3=Claudio|last4=L|first4=Zhuang|last5=B|first5=Patterson|last6=Ak|first6=Stewart|date=2006|title=Analysis of PTEN deletions and mutations in multiple myeloma|url=https://pubmed.ncbi.nlm.nih.gov/16112193/|language=en|pmid=16112193}}</ref> |
| |- | | |- |
| | rowspan="6" |11 | | | rowspan="6" |11 |
Line 346: |
Line 511: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |11p | | |11p |
Line 353: |
Line 518: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |11q | | |11q |
Line 360: |
Line 525: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" />, 23010713 (2012)<ref name=":6" /> | + | |<ref name=":2" /> <ref name=":6" /> |
| |- | | |- |
− | |11q13.1/q13.4 | + | | 11q13.1/q13.4 |
| |Gain | | |Gain |
− | |''SCYL1, MAP3K11, CCND1, FGF4, FGF3, NUMA,'' and ''RELT'' | + | |''[[SCYL1]], [[MAP3K11]], [[CCND1]], [[FGF4]], [[FGF3]], [[NUMA]]'' and ''[[RELT]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5" /> | + | |<ref name=":5" /> |
| |- | | |- |
| |11q22 | | |11q22 |
Line 374: |
Line 539: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |11q22.1-q22.3 | | |11q22.1-q22.3 |
| |Homozygous Loss | | |Homozygous Loss |
− | |BIRC3, BIRC2, MMP cluster | + | |[[BIRC3]], [[BIRC2]], MMP cluster |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" />, 22529291 (2012)<ref>{{Cite journal|last=Jb|first=Egan|last2=Cx|first2=Shi|last3=W|first3=Tembe|last4=A|first4=Christoforides|last5=A|first5=Kurdoglu|last6=S|first6=Sinari|last7=S|first7=Middha|last8=Y|first8=Asmann|last9=J|first9=Schmidt|date=2012|title=Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides|url=https://pubmed.ncbi.nlm.nih.gov/22529291/|language=en|doi=10.1182/blood-2012-01-405977|pmc=PMC3412329|pmid=22529291}}</ref> | + | |<ref name=":1" /> <ref>{{Cite journal|last=Jb|first=Egan|last2=Cx|first2=Shi|last3=W|first3=Tembe|last4=A|first4=Christoforides|last5=A|first5=Kurdoglu|last6=S|first6=Sinari|last7=S|first7=Middha|last8=Y|first8=Asmann|last9=J|first9=Schmidt|date=2012|title=Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides|url=https://pubmed.ncbi.nlm.nih.gov/22529291/|language=en|doi=10.1182/blood-2012-01-405977|pmc=PMC3412329|pmid=22529291}}</ref> |
| |- | | |- |
| | rowspan="3" |12 | | | rowspan="3" |12 |
Line 389: |
Line 554: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":5" /> <ref name=":7" /> |
| |- | | |- |
| |12p | | |12p |
Line 396: |
Line 561: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" />, 22833442 (2012)<ref name=":7" /> | + | |<ref name=":2" /> <ref name=":7" /> |
| |- | | |- |
| |12p13.1 | | |12p13.1 |
| |Loss | | |Loss |
− | |''CDKN1B, APOLD1'' | + | |''[[CDKN1B]], [[APOLD1]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| | rowspan="3" |13 | | | rowspan="3" |13 |
− | |13q/13 | + | | 13q/13 |
| |Loss | | |Loss |
| | | | | |
| |Poor prognostic marker | | |Poor prognostic marker |
| |1 | | |1 |
− | |25145975 (2015)<ref name=":2" /> 24987674 (2014)<ref name=":1" />, 22833442 (2012)<ref name=":7" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" />, 27588520 (2016)<ref name=":8" />, | + | |<ref name=":1" /> <ref name=":2" /> <ref name=":7" /> <ref name=":6" /> <ref name=":5" /> <ref name=":8" /> |
| |- | | |- |
| |13q14.11/q14.2 | | |13q14.11/q14.2 |
| |Loss | | |Loss |
− | |''TNFSF11, RB1, P2RY5, RCBTB2'' | + | |''[[TNFSF11]], [[RB1]], [[P2RY5]], [[RCBTB2]]'' |
| |Poor prognostic marker | | |Poor prognostic marker |
| |1 | | |1 |
− | |24757046 (2014)<ref name=":5" />, 24987674 (2014)<ref name=":1" />, 25636340 (2015)<ref name=":0" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":5" /> |
| |- | | |- |
| |13q32.2 | | |13q32.2 |
| |Loss | | |Loss |
− | |''TGDS'' | + | |''[[TGDS]]'' |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |24429703-(2014)<ref name=":4" /> | + | |<ref name=":4" /> |
| |- | | |- |
| | rowspan="5" |14 | | | rowspan="5" |14 |
− | |14q/14 | + | | 14q/14 |
| |Loss | | |Loss |
| | | | | |
| |Better prognostic marker | | |Better prognostic marker |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" />, 25145975 (2015)<ref name=":2" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":2" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |14q/14 | | |14q/14 |
Line 440: |
Line 605: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |23010713 (2012)<ref name=":6" /> | + | |<ref name=":6" /> |
| |- | | |- |
| |14q | | |14q |
Line 447: |
Line 612: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" />, 22833442 (2012)<ref name=":7" /> | + | |<ref name=":2" /> <ref name=":7" /> |
| |- | | |- |
| |14q24.1-q24.3 | | |14q24.1-q24.3 |
| |Loss | | |Loss |
− | |''MLH3'' | + | |''[[MLH3]]'' |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |14q32.32 | | |14q32.32 |
| |Homozygous Loss | | |Homozygous Loss |
− | |''RCOR1, TRAF3, AMN, CDC42BPB'' | + | |''[[RCOR1]], [[TRAF3]], [[AMN]], [[CDC42BPB]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| | rowspan="2" |15 | | | rowspan="2" |15 |
Line 469: |
Line 634: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" /> 25145975 (2015)<ref name=":2" /> | + | |<ref name=":1" /> <ref name=":2" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |15q24.1 | | |15q24.1 |
| |Gain | | |Gain |
− | |''CYP11A1, ARID3B, CSK, etc.'' | + | |''[[CYP11A1]], [[ARID3B]], [[CSK]], etc.'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| | rowspan="5" |16 | | | rowspan="5" |16 |
| |16p11.2 | | |16p11.2 |
| |Loss | | |Loss |
− | |''TP53TG3'' | + | |''[[TP53TG3]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |16q | | |16q |
Line 491: |
Line 656: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |25636340 (2015)<ref name=":0" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |16q12.1-q12.2 | | |16q12.1-q12.2 |
| |Homozygous Loss | | |Homozygous Loss |
− | |''CYLD, SALL1'' | + | |''[[CYLD]], [[SALL1]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |16q24.3 | | |16q24.3 |
| |Loss | | |Loss |
− | |CBFA2T3 and others | + | |''[[CBFA2T3]]'' and others |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24757046 (2014)<ref name=":5" /> | + | |<ref name=":5" /> |
| |- | | |- |
| |16 | | |16 |
| |cnLOH | | |cnLOH |
| | | | | |
− | |Recurrent | + | | Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" /> | + | |<ref name=":7" /> |
| |- | | |- |
| | rowspan="6" |17 | | | rowspan="6" |17 |
Line 520: |
Line 685: |
| |Recurrent | | |Recurrent |
| |3, 3 | | |3, 3 |
− | |23010713 (2012)<ref name=":6" />, 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":6" /> |
| |- | | |- |
| |17p | | |17p |
Line 527: |
Line 692: |
| |Predictive & prognostic | | |Predictive & prognostic |
| |1 | | |1 |
− | |22833442 (2012)<ref name=":7" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" />, 24429703-(2014)<ref name=":4" /> | + | |<ref name=":4" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
− | |17p13 | + | | 17p13 |
| |Loss | | |Loss |
− | |''ATP1B2, '''TP53''', WRAP5, EFNB3'' | + | |''[[ATP1B2]], [[TP53]], [[WRAP5]], [[EFNB3]]'' |
− | |Predictive & prognostic | + | | Predictive & prognostic |
| |1 | | |1 |
− | |24987674 (2014)<ref name=":1" />, 27588520 (2016)<ref name=":8" /> | + | |<ref name=":1" /> <ref name=":8" /> |
| |- | | |- |
| |17 | | |17 |
Line 541: |
Line 706: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" /> | + | |<ref name=":7" /> |
| |- | | |- |
| |17q21.33 and 17qter | | |17q21.33 and 17qter |
Line 548: |
Line 713: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |17q25 | | |17q25 |
Line 555: |
Line 720: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" /> | + | |<ref name=":7" /> |
| |- | | |- |
| |18 | | |18 |
Line 563: |
Line 728: |
| |Recurrent | | |Recurrent |
| |2, 3 | | |2, 3 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":7" /> |
| |- | | |- |
| | rowspan="3" |19 | | | rowspan="3" |19 |
Line 571: |
Line 736: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" />, | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |19p/ 19p13 | | |19p/ 19p13 |
| |Gain | | |Gain |
− | |''ICAM4,ICAM4, IBCL2L12, TYK2, IL2,'' and ''DNMT1'' | + | |''ICAM4, ICAM4, [[IBCL2L12]], [[TYK2]], [[IL2]]'' and ''[[DNMT1]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" />, 26912802 (2016)<ref name=":3" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":3" /> <ref name=":5" /> |
| |- | | |- |
| |19q | | |19q |
Line 585: |
Line 750: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |24987674 (2014)<ref name=":1" />, 25145975 (2015)<ref name=":2" /> | + | |<ref name=":1" /> <ref name=":2" /> |
| |- | | |- |
| | rowspan="3" |20 | | | rowspan="3" |20 |
Line 593: |
Line 758: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":7" /> |
| |- | | |- |
| |20/20q | | |20/20q |
Line 600: |
Line 765: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> <ref name=":7" /> |
| |- | | |- |
| |20/20q | | |20/20q |
Line 607: |
Line 772: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" /> | + | |<ref name=":1" /> <ref name=":6" /> |
| |- | | |- |
| |21 | | |21 |
Line 615: |
Line 780: |
| |Recurrent | | |Recurrent |
| |1 | | |1 |
− | |22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 23010713 (2012)<ref name=":6" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| | rowspan="2" |22 | | | rowspan="2" |22 |
Line 623: |
Line 788: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" />, 23010713 (2012)<ref name=":6" />, 22833442 (2012)<ref name=":7" />, 24987674 (2014)<ref name=":1" />, 24757046 (2014)<ref name=":5" /> | + | |<ref name=":0" /> <ref name=":1" /> <ref name=":5" /> <ref name=":6" /> <ref name=":7" /> |
| |- | | |- |
| |22q21 | | |22q21 |
| |mostly Gain | | |mostly Gain |
− | |''PRAME'' | + | |''[[PRAME]]'' |
| |Recurrent, Associated with relapse | | |Recurrent, Associated with relapse |
| |2 | | |2 |
− | |27811368-(2016)<ref name=":9" /> | + | |<ref name=":9" /> |
| |- | | |- |
| | rowspan="8" |X | | | rowspan="8" |X |
| |X | | |X |
− | |Gain/ Loss | + | |Gain / Loss |
| | | | | |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |22833442 (2012)<ref name=":7" />, 25145975 (2015)<ref name=":2" /> | + | |<ref name=":2" /> <ref name=":7" /> |
| |- | | |- |
| |X | | |X |
Line 645: |
Line 810: |
| |Recurrent | | |Recurrent |
| |2 | | |2 |
− | |25145975 (2015)<ref name=":2" /> | + | |<ref name=":2" /> |
| |- | | |- |
| |Xp | | |Xp |
Line 652: |
Line 817: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |Xp22.33 | | |Xp22.33 |
| |Loss | | |Loss |
− | |''SHOX, CRLF2, IL3RA'' | + | |''[[SHOX]], [[CRLF2]], [[IL3RA]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |Xq | | |Xq |
Line 666: |
Line 831: |
| |Poor prognostic marker | | |Poor prognostic marker |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" />, 24987674 (2014)<ref name=":1" /> | + | |<ref name=":0" /> <ref name=":1" /> |
| |- | | |- |
| |Xq | | |Xq |
Line 673: |
Line 838: |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |24987674 (2014)<ref name=":1" /> | + | |<ref name=":1" /> |
| |- | | |- |
| |Xq21.31-q21.32 | | |Xq21.31-q21.32 |
| |Loss | | |Loss |
− | |''PABPC5, PCDHX'' | + | |''[[PABPC5]], [[PCDHX]]'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |Xq27.3-q28 | | |Xq27.3-q28 |
| |Gain | | |Gain |
− | |''AFF2, MTMR1, etc'' | + | |''[[AFF2]], [[MTMR1]], etc'' |
| |Recurrent | | |Recurrent |
| |3 | | |3 |
− | |26912802 (2016)<ref name=":3" /> | + | |<ref name=":3" /> |
| |- | | |- |
| |Y | | |Y |
Line 695: |
Line 860: |
| | | | | |
| |2 | | |2 |
− | |25636340 (2015)<ref name=":0" /> | + | |<ref name=":0" /> |
| |- | | |- |
| |Genome wide load of CNA > 100Mb | | |Genome wide load of CNA > 100Mb |
| | | | | |
− | |gain/loss | + | |Gain / Loss |
| | | | | |
| |associated with significant change in GEP at relapse | | |associated with significant change in GEP at relapse |
| |2 | | |2 |
− | |27811368-(2016)<ref name=":9" /> | + | |<ref name=":9" /> |
| |} | | |} |
| + | cnLOH = copy neutral LOH, LOH = Loss of Heterozygosity, GEP = Gene Expression Profile |
| + | |
| + | '''Level of evidence:''' |
| + | |
| + | Level 1: well established evidence (in NCCN guideline, WHO criteria, FDA-approved, COG recommendation, or based on large body of publications) |
| + | |
| + | Level 2: emerging evidence (by one large study or multiple case reports) |
| + | |
| + | Level 3: presumptive evidence (multiple case reports or expert opinion) |
| + | |
| + | ==Reference== |
| <references /> | | <references /> |